RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

Prior treatment

• Exposure to the following medications in the prior 12 months;
• Solid organ transplant, or expecting a solid organ transplant
• Bone marrow transplant
• Currently enrolled in another research study that requires taking medication

Other illness

• Diagnosis of the following medical conditions;
• Addison's disease
• Adrenal insufficiency
• History of metabolic bone disease (except osteoporosis) such as Paget's disease, osteomalacia, osteogenesis imperfecta, or Cushing's disease
• Pathologic fractures secondary to malignancy or infection
• Participant unable to consent on their own (cognitive impairment, dementia, etc.)

Other

• Actonel or Atelvia (risedronate)
• Fosamax or Binosto (alendronate)
• Reclast, Zometa, or Aclasta (zoledronic acid, zoledronate)
• Boniva or Bondronat (ibandronate)
• Aredia (pamidronate)
• Prolia (denosumab)
• Evenity (romozosumab)
• Tymlos (abaloparatide)
• Forteo (teriparatide)
• Natpara (parathyroid hormone)
• Evista (raloxifene)
• Duavee (bazedoxifene-conjugated estrogen)
• Miacalcin (calcitonin)
• CKD stage 4 or 5 or on dialysis
• Multiple myeloma
• Enrolled hospice care
• Fractures resulting from severe trauma (e.g. motor vehicle accidents, a fall from 2 feet or higher elevation)
• Scheduled appointment with a bone health specialist

• Age 50 years and older (no upper age limit)
• Sustained a primary fragility fracture (hip/femur, pelvis, clinical spine, humerus, wrist) in the last 12 months
• Participant must self-identify a regular primary care provider (PCP)
• Participant must provide a mailing address
• Participant must plan to remain geographically proximate (able to travel if necessary) to the site from which they are recruited over the next several months